Doctor consulting with patient in hospital waiting area

For Patients

Understanding Multiple Myeloma

Understanding Multiple Myeloma

A diagnosis of multiple myeloma can feel overwhelming, and understanding the disease is often the first step toward making informed decisions about your care. Multiple myeloma is a type of blood cancer that affects plasma cells, which are responsible for helping the body fight infections.

Every patient's myeloma is unique. The genetic changes driving the disease can vary from person to person and may influence how the disease behaves and responds to treatment. Understanding these genetic differences can provide valuable information to your healthcare team.

PlasmaSEQ is an advanced genomic testing solution designed to identify important genetic changes associated with multiple myeloma. By providing a more comprehensive view of the disease, PlasmaSEQ helps physicians better understand a patient's risk profile and make more informed treatment decisions.

Our goal is to support patients and healthcare providers with accurate genomic insights that can contribute to more personalized care throughout the treatment journey.

The PlasmaSEQ Process

The PlasmaSEQ Process

While FISH tests have been the standard in myeloma for almost 2 decades now, they are extremely limiting in terms of resolution. FISH can in general only identify abnormalities that involve at least 100,000 to 200,000 abnormal DNA molecules.

PlasmaSEQ however can do this at a resolution of 1 abnormal DNA molecule thus bringing a new paradigm to myeloma care.

In Multiple Myeloma (MM), NGS has been used to explore the genomic landscape and identify key genetic mutations. However, it has yet to be widely adopted in routine clinical practice worldwide.

Key Benefits

Why PlasmaSEQ

Comprehensive Testing in a Single Assay – PlasmaSEQ evaluates multiple important genetic markers through a single comprehensive test, reducing the need for multiple separate analyses.

Advantages

  • Works with Limited Sample Volumes – Designed to generate meaningful results even from limited biological material.
  • Deeper Genetic Insights – Provides a more detailed understanding of the genetic changes associated with multiple myeloma.
  • A More Complete View of Your Disease – Helps physicians better understand the unique genetic profile of your myeloma.
  • Timely Results – Delivers results efficiently to support faster clinical decision-making.
  • Expert Review – Results are reviewed by professionals with expertise in multiple myeloma and genomic analysis.

FAQs

Multiple myeloma can vary significantly from one patient to another. PlasmaSEQ helps identify important genetic changes associated with the disease, providing your healthcare team with additional information to guide treatment decisions.

PlasmaSEQ uses advanced genomic sequencing technology to evaluate a broad range of genetic changes associated with multiple myeloma. This comprehensive approach can provide deeper insights into the disease and support more personalized treatment planning.

PlasmaSEQ provides important genomic information that can help physicians better understand the characteristics of your disease. Your healthcare provider will use these results, along with other clinical information, to determine the most appropriate treatment plan.

Yes. PlasmaSEQ testing is performed at NCGM, a CAP- and CLIA-accredited genomic laboratory committed to maintaining high standards of quality and reliability.

Turnaround times may vary depending on the specimen received and testing requirements. Please speak with your healthcare provider regarding expected reporting timelines.